The Effective Targeting of KRASG12C Elusiveness

被引：1

作者：

Elez, Filiation Elena ^{[1
]}

Tabernero, Josep ^{[1
]}

机构：

[1] Univ Autonoma Barcelona UAB, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

来源：

CANCER CELL | 2020年 / 38卷 / 06期

关键词：

MECHANISM; KRAS;

D O I：

10.1016/j.ccell.2020.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.

引用

页码：785 / 787

页数：3

共 50 条

[21] Assessment of KRASG12C inhibitors for colorectal cancer
Piazza, Gary A.
Chandrasekaran, Preethi
Maxuitenko, Yulia Y.
Budhwani, Karim I.
FRONTIERS IN ONCOLOGY, 2024, 14
[22] Acquired Resistance to KRASG12C Inhibition in Cancer
Awad, M. M.
Liu, S.
Rybkin, I. I.
Arbour, K. C.
Dilly, J.
Zhu, V. W.
Johnson, M. L.
Heist, R. S.
Patil, T.
Riely, G. J.
Jacobson, J. O.
Yang, X.
Persky, N. S.
Root, D. E.
Lowder, K. E.
Feng, H.
Zhang, S. S.
Haigis, K. M.
Hung, Y. P.
Sholl, L. M.
Wolpin, B. M.
Wiese, J.
Christiansen, J.
Lee, J.
Schrock, A. B.
Lim, L. P.
Garg, K.
Li, M.
Engstrom, L. D.
Waters, L.
Lawson, J. D.
Olson, P.
Lito, P.
Ou, S. -H. I.
Christensen, J. G.
Janne, P. A.
Aguirre, A. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25): : 2382 - 2393
[23] Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Santana-Codina, Naiara
Chandhoke, Amrita Singh
Yu, Qijia
Malachowska, Beata
Kuljanin, Miljan
Gikandi, Ajami
Stanczak, Marcin
Gableske, Sebastian
Jedrychowski, Mark P.
Scott, David A.
Aguirre, Andrew J.
Fendler, Wojciech
Gray, Nathanael S.
Mancias, Joseph D.
CELL REPORTS, 2020, 30 (13): : 4584 - +
[24] Targeting KRASG12C: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Kabir, E. R.
Tanisha, M. Haque
Sagar, B. Hossain
Mollika, R.
Khan, T. T. S.
Chowdhury, N. M.
Yasmin, H.
Khair, N. Z.
Quadir, M.
Mustafa, N.
ANNALS OF ONCOLOGY, 2022, 33 : S1611 - S1611
[25] KRASG12C inhibition synergizes with checkpoint blockade in KRASG12-Cmutated tumor model
Hua, Li
Li, Shuang
Nie, Chenpan
Zhang, Chenfei
Bourre, Ludovic
Wang, Jingjing
CANCER RESEARCH, 2024, 84 (06)
[26] Understanding the basis for acquired resistance to KRASG12C inhibitors
Santos Ramos, A.
Gomez Sanchez, D.
Rico Lopez, S.
Plaza Exposito, P.
Paz-Ares, L.
Ferrer Sanchez, I.
ANNALS OF ONCOLOGY, 2022, 33 (08) : S1411 - S1411
[27] Oncogenic KRASG12C dependency in colorectal cancer.
Coker, Oluwadara
Sorokin, Alexey
Gale, Kelly
Gao, Fengqin
Shen, John Paul
Kwong, Lawrence
Wu, Ji
Lee, Hey Min
Woods, Melanie
Villareal, Oscar
Kopetz, Scott
CANCER RESEARCH, 2021, 81 (13)
[28] A Novel Inhibitor for KRASG12C Mutant Lung Carcinoma
Khan, H. Y.
Li, Y.
Aboukameel, A.
Mpilla, G.
Sexton, R.
Kanbur, T.
Cetinkaya, H.
Cagir, A.
Al-Hallak, M. N.
Sukari, A.
Azmi, A. S.
Nagasaka, M.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S15 - S15
[29] Discovery of Quinazoline Derivatives as Potent KRASG12C Inhibitors
Liu, Nian
Li, Zhilong
Liu, Rui
Zhang, Chaoxin
Sun, Yixiang
Ma, Xing
Qin, Qiaohua
Wu, Tianxiao
Sun, Yin
Yin, Wenbo
Zhang, Haoyu
Gao, Zixuan
Xia, Guangxin
Zhao, Dongmei
Cheng, Maosheng
CHEMISTRYSELECT, 2024, 9 (39):
[30] Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Santos Ramos, A.
Gomez Sanchez, D.
Plaza Exposito, P.
Paz-Ares, L.
Ferrer Sanchez, I.
ANNALS OF ONCOLOGY, 2023, 34 : S753 - S753

← 1 2 3 4 5 →